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CLINICAL INVESTIGATION
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Diagnostic value of bone marrow biopsy in patients with renal disease
secondary to familial Mediterranean fever. Systemic AA type amyloid-
osis with renal involvement is the major cause of morbidity and
mortality in patients with familial Mediterranean fever (FMF). A
histopathological examination is essential to achieve a definite diagnosis
in systemic amyloidosis. The diagnostic yield of the procedure varies
according to the biopsy site and renal biopsy has the highest yield. On
the other hand this procedure has its own complications and requires
hospitalization of the patient. Alternative biopsy sites have been
proposed with varying degrees of sensitivity and morbidity to reduce
the morbidity and mortality of solid organ biopsies. We performed bone
marrow biopsies in 39 patients with FMF who had different stages of
renal disease. Thirty-one (79.5%) of the 39 specimens showed signifi-
cant perivascular amyloid infiltration when stained with crystal violet
and Congo red. An immunoperoxidase stain with a monoclonal anti-
body proved that these deposits were AA type amyloid. We suggest
that bone marrow biopsy can be utilized for a safe and quick diagnosis
of systemic amyloidosis in patients with FMF and renal disease.
Familial Mediterannean fever, which is an autosomally reces-
sive disorder affecting several ethnic groups in Middle East and
Mediterranean countries, is characterized by a high incidence
(60%) of AA-type systemic amyloidosis and is a common cause
of end-stage renal disease in the Turkish population [1]. Clinical
course of renal amyloidosis usually follows a step-wise progres-
sion, extending from asymptomatic proteinuria to end-stage
renal disease. Renal failure is the leading cause of morbidity and
mortality in patients with FMF [2]. Studies of the last decade
have enabled us to differentiate different forms of protein
components leading to amyloid deposition [3]. These advances
in amyloid research will provide new diagnostic and therapeutic
approaches, but two fundamental issues of amyloidosis remain
unchanged: (1) The precursor protein may vary but the eventual
point is the deposition of amyloid fibrils around the walls of
small blood vessels; (2) A histopathological examination is
required for a definite diagnosis [4]. Several biopsy sites with
different sensitivities have been proposed to diagnose AA
amyloidosis with renal involvement and patients with systemic
amyloidosis are at increased risk for hemorrhagic complications
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after solid organ biopsies because of their well-defined coagu-
lation defects [51. Bone marrow is abundant in small blood
vessels and reticuloendothelial cells, and it has been shown that
amyloid deposition in the bone marrow can be detected in 30 to
50% of patients with primary amyloidosis [6].
The aim of this study was to evaluate the diagnostic yield of
bone marrow biopsy in patients with clinically overt renal
disease due to FMF in order to offer a safe, quick and sensitive
diagnostic approach.
Methods
Clinical features
Thirty-nine patients with FMF and renal disease were eva!-
uated in the Nephrology Unit of Hacettepe University, School
of Medicine, Ankara. Twenty-five of them were registered in
the FMF Registry Group of Hacettepe University Hospital,
Departments of Pediatrics and Internal Medicine. A positive
family history and typical progression of the disease was
noticed in their childhood, and elevation of fibrinogen levels
and other acute phase reactants together with leukocytosis
during acute attacks were also observed. These patients were
prescribed coichicine and offered a follow-up program but were
not compliant with their treatment and program. The other 14
patients also had a positive family history and characteristic
clinical and laboratory findings, but were referred to our hos-
pital after developing renal complications. Twenty were male
and 19 female, with an average age of 29 4. Twenty patients
(51.3%) had nephrotic syndrome with creatinine clearance
values over 60 mI/mm, 15 patients (38.5%) had chronic renal
failure with creatinine clearance values below 30 mI/mm and
four patients (10.3%) were on a regular dialysis program.
Fourteen patients had a previous histopathological diagnosis
with a renal biopsy and 11 patients with a rectal biopsy. In the
remaining 14 patients a histopathological examination had not
been performed before.
Laboratory data
Twenty-five patients (64.1%) had enlarged kidneys and 12
(30.8) had normal sized kidneys on ultrasonographic examina-
tion. Two patients on the regular dialysis program had bilateral
contracted kidneys which also had cyst formation. All of
the patients were anemic and their mean hemoglobin and
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Fig. 1. Amyloid deposition around a blood
vessel. Bone marrow biopsy (Crystal violet, x
230). Publication of Figures 1, 2, and 3 in
color was made possible by a joint grant from
Dako (Glastrup, Denmark) and the
International Society of Nephrology.
Fig. 2. Birefrigerence under polarized light of
amyloid deposits in the bone marrow (Congo
red, x 115).
Fig. 3. Immunoperoxidase stain for AA type
amyloid (Streptavidin-biotin complex x 460).
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NS CRF ESRD
Total
N
Yield
%
Initial bone marrow biopsy 7 4 — 14 78,6
Patients with a previous
positive biopsy
Rectal 3 4 4 II
Bone marrow 3 3 3 14 81.8
Renal 7 5 2
Bone marrow 7 3 1 78.6
Abbreviations are: NS, nephrotic syndrome; CRF, chronic renal
failure; ESRD, end-stage renal disease.
hematocrit values were 9.4 2 g/dl and 26 2%, respectively.
No evidence of urinary monoclonal light chain excretion was
observed by immunoelectrophoresis.
Pathological methods
Posterior superior iliac crest was the preferred biopsy site
and the specimens were obtained with a modified Jamshidi
needle as an outpatient procedure. No complications were
observed. Bone marrow biopsies averaging 10 mm in length
were decalcified and stained with hematoxylin eosin (H + E),
crystal violet and Congo red in the Pathology Department, and
examinations were made with light microscopy and under
polarized light. In order to prove that amyloid deposits were
AA type, an immunoperoxidase (avidin-biotin) staining with a
monoclonal antibody against AA type amyloid (DAKO) was
used. The sections were regarded as inadequate if they did not
contain at least three blood vessels.
Results
In 31 of 39 patients with FMF and renal disease (79.5%)
amyloid deposits were detected around the blood vessels in the
bone marrow biopsies. There was a complete correlation of
crystal violet and Congo red stains, and all of the 31 specimens
were positive for amyloid with both of these stains (Figs. 1 and
2). Immunoperoxidase staining proved that the deposits were
AA type amyloid in these 31 patients (Fig. 3). Thirty-nine of the
bone marrow biopsies were normocellular and seven showed
slight erythroid hyperplasia. Plasmacytosis and presence of
atypical plasma cells were not detected in any of these 39
patients. In two of the patients on regular dialysis, three of the
patients with chronic renal failure and three patients with
nephrotic syndrome, bone marrow examinations failed to dem-
onstrate amyloid deposition. In one patient with nephrotic
syndrome a rectal biopsy demonstrated the presence of amyloid
deposition, while in two patients rectal biopsies were also
negative and renal biopsies yielded the diagnosis. The other
four patients had been subject to renal biopsies before, which
demonstrated renal amyloidosis.
In 14 of the patients without a previous biopsy, 11 specimens
demonstrated amyloid deposition in the bone marrow (78.6%).
Four of these patients had chronic renal failure and seven had
nephrotic syndrome. Rectal biopsies of the remaining two
patients with nephrotic syndrome were also negative and the
diagnosis was achieved by a renal biopsy as mentioned above.
These findings are summarized in Table 1.
Discussion
Bone marrow biopsy has a diagnostic yield of 30 to 50% in
patients with AL type primary amyloidosis and may be referred
as the initial diagnostic site [7, 8]. On the other hand, subcuta-
neous fat aspiration, gingiva and rectal biopsies are employed in
the diagnosis of AA amyloidosis secondary to FMF with renal
involvement, if solid organ biopsy is contraindicated [9]. Rectal
biopsy has a diagnostic yield of 75 to 85% if an adequate
submucosal specimen is obtained but is also associated with a
bleeding risk and bacteremia [10]. It also requires an endo-
scopic procedure done by a skilled endoscopist and may cause
patient discomfort. This study suggests that bone marrow
biopsy has an overall diagnostic yield in the diagnosis of AA
type systemic amyloidosis in 79.5% of patients with overt
clinical renal disease in patients with FMF. Furthermore, it
provided an initial diagnosis of AA type systemic amyloidosis in
11 of 14 patients (78.6%). Percutaneous bone marrow biopsy is
a safe method and can be performed as an outpatient procedure.
The biopsy procedure does not require specialized instruments
and personnel. This diagnostic approach cannot detect immune
mediated glomerular diseases which are common in some
ethnic groups with FMF [11]. On the other hand, it has the
advantage of providing data about the hematologic profile of
these patients with renal disease and may be helpful for issues
such as: response to colchicine, monitorization of erythropoie-
tin treatment, detection of macrophage iron stores and alumi-
num toxicity. The diagnostic value of bone marrow biopsy in
earlier stages of the disease, when clinical signs of renal
amyloidosis are not evident, is yet to be determined.
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Table 1. Diagnostic value of bone marrow biopsy in the detection of
AA type amyloidosis in 39 patients with FMF and renal disease
